Cetera Advisor Networks LLC Galectin Therapeutics Inc Transaction History

Cetera Advisor Networks LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$2.07 - $5.1 $33,132 - $81,630	-16,006 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$2.53 - $3.64 $1,151 - $1,656	-455 Reduced 2.76%	16,006 $43,000
Q3 2019 Nov 06, 2019	SELL	$3.0 - $4.05 $7,680 - $10,368	-2,560 Reduced 13.46%	16,461 $60,000
Q4 2018 Feb 15, 2019	SELL	$3.43 - $5.74 $50,421 - $84,378	-14,700 Reduced 43.59%	19,021 $66,000
Q2 2018 Aug 14, 2018	BUY	$3.16 - $9.16 $106,558 - $308,884	33,721 New	33,721 $215,000

Q1 2018 May 09, 2018	SELL	$3.78 - $5.97 $59,425 - $93,854	-15,721 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	15,721	15,721 $38,000

7.62M

61.2K

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $135M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Cetera Advisor Networks LLC, based on Form 13F filings with the SEC.

Stay updated on Cetera Advisor Networks LLC with notifications on news.